FTA to batter generic drug business and raise patent disputes.

Published: 2007-04-06 06:57:00

Updated: 2007-04-06 06:57:00

It is expected that the KORUS FTA settlement may raise a lot of patent disputes between the original drug companies and generic drug manufacturers, and if any patent lawsuit be raised, its copy drug registration may be decided to cancel at the KFDA within one year after its file.

The recognit...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK